Drug class may be linked to fewer deaths in low-protein kidney disease
Estimated three-year mortality was 14.88% among adults who started renin-angiotensin system inhibitors, versus 18.26% among controls, in an observational study.
3 years
Limit: The abstract does not report drug doses or adverse events
Edited by Boris Djordjevic · AgingResearch.News
An observational study analyzed records from 10,101 adults in China with chronic kidney disease and low levels of albumin, a protein, in their urine. Researchers used existing records to mimic a series of trials. They compared starting renin-angiotensin system inhibitors, drugs used for kidney disease, with not starting them.
Starting the drugs was associated with a 3.39-percentage-point lower estimated risk of death from any cause over three years. The estimated difference for deaths from heart and blood vessel disease was 1.46 percentage points. A combined outcome of worsening kidney function or treatment to replace kidney function showed no clear difference between groups.
Why it matters
Treatment options are limited for chronic kidney disease without elevated urine protein. Whether existing drugs can help this group bears on reducing the burden of kidney disease in later life.
Caveats
This observational analysis mimicked trials but could not rule out other differences between groups accounting for the associations. The findings concern adults with chronic kidney disease and low urine albumin; the abstract does not report drug doses or adverse events.
- Renin-angiotensin system inhibitors
- Renin–angiotensin system
- Nonproteinuric chronic kidney disease
- Estimated glomerular filtration rate
- Urine albumin-to-creatinine ratio
- Humans
The paper
Nanfang Hospital
Clinical Kidney Journal, Oct 28, 2026, Open access, CC BY-NC
Comments
Be the first to comment.